[1] Fontaine J, Joly P, Roujeau JC. Treatment of bullous pemphigoid. J Dermatol, 2003, 30:83-90. [2] 朱学骏,郭英年.大疱性类天疱疮的糖皮质激素治疗.中华皮肤科杂志,1986,19:282-283. [3] 徐参,姚志远,汪晨.20例天疱疮及类天疱疮糖皮质激素用量分析报告.临床皮肤科杂志,1990,19:185-187. [4] 朱学骏,李冠群,郭英年.52例大疱性类天疱疮的预后及影响因素分析.中华皮肤科杂志,1993,26:116-117. [5] 林麟,靳培英,王峰来,等.大疱性类天疱疮抗原分子异质性与临床的关系中华皮肤科杂志,1997,30:13-15 [6] Tanaka M, Hashimoto T, Dykes PJ, et al. Clinical manifestations in100 Japanese bullous pemphigoid cases in relation to antoantigen profiles. Clin Exp Dermatol, 1996, 21:23-27. [7] Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2-and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol, 2002, 119,1065-1073. |